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Abstract
Background: Resistance to modern adjuvant treatment is in part due to the failure of
programmed cell death. Therefore the molecules that execute the apoptotic program are potential
targets for the development of anti-cancer therapeutics. The sigma-2 receptor has been found to
be over-expressed in some types of malignant tumors, and, recently, small molecule ligands to the
sigma-2 receptor were found to induce cancer cell apoptosis.
Results: The sigma-2 receptor was expressed at high levels in both human and murine pancreas
cancer cell lines, with minimal or limited expression in normal tissues, including: brain, kidney, liver,
lung, pancreas and spleen. Micro-PET imaging was used to demonstrate that the sigma-2 receptor
was preferentially expressed in tumor as opposed to normal tissues in pancreas tumor allograft-
bearing mice. Two structurally distinct sigma-2 receptor ligands, SV119 and WC26, were found to
induce apoptosis to mice and human pancreatic cancer cells in vitro and in vivo. Sigma-2 receptor
ligands induced apoptosis in a dose dependent fashion in all pancreatic cell lines tested. At the
highest dose tested (10 µM), all sigma-2 receptor ligands induced 10–20% apoptosis in all pancreatic
cancer cell lines tested (p < 0.05). In pancreas tumor allograft-bearing mice, a single bolus dose of
WC26 caused approximately 50% apoptosis in the tumor compared to no appreciable apoptosis
in tumor-bearing, vehicle-injected control animals (p < 0.0001). WC26 significantly slowed tumor
growth after a 5 day treatment compared to vehicle-injected control animals (p < 0.0001) and
blood chemistry panels suggested that there is minimal peripheral toxicity.
Conclusion: We demonstrate a novel therapeutic strategy that induces a significant increase in
pancreas cancer cell death. This strategy highlights a new potential target for the treatment of
pancreas cancer, which has little in the way of effective treatments.
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Pancreas cancer is the fourth most common cause of can-
cer-related mortality in the United States[1]. There has
been little progress in the management of this disease and
the annual mortality rate remains nearly identical to the
annual incidence rate. There were an estimated 37,000
deaths attributable to this disease in the United States in
2006[1]. The five-year survival for patients diagnosed with
pancreas cancer is only 4%. Poor outcome is the result of
difficulty in achieving early diagnosis and failure of mod-
ern treatments including surgery, radiation and chemo-
therapy. Normally, chemotherapy and radiation therapy
for pancreatic cancer is palliative. For localized disease
surgery remains the single most effective therapy, however
even with complete surgical resection, the prognosis
remains dismal and the majority of patients recur with
systemic metastases. Therefore there is a critical need for
an effective systemic therapy utilizing a new strategy.
Programmed cell death or apoptosis is an essential proc-
ess in cell homeostasis and eukaryotic development[2,3].
Recent studies have shown that failure of apoptosis is
both central to the evolution of cancer and related to
resistance toward modern adjuvant treatment such as
chemo- or radiation therapies [4-6]. Therefore, there is
considerable interest in targeting the molecular pathways
of apoptosis as a component of cancer therapy.
We and others have recently reported that intracellular
delivery of pro-apoptotic peptides can induce apoptosis in
cancer cells in vitro and in animal models of adenocarci-
nomas in vivo [7-9]. For example, we have studied TAT-
Bim a dual domain molecule comprised of an internaliza-
tion motif (the polybasic region of HIV-1 TAT) and a bio-
logical effector domain (the BH3 domain of Bim) which
leads to apoptosis. To demonstrate anti-tumor effective-
ness in vivo, the peptides were injected intra-tumorally due
to the non-specific cell permeation capacity of the TAT
peptide[10]. Direct intra-tumoral injection of the TAT-
Bim compound effectively reduced tumor size and pro-
longed survival in animal models of pancreatic cancer[9].
In order to translate these promising anti-cancer
approaches into clinically viable therapies, cancer cell-
specific targeting is required. The targeting strategy or
domain can then be combined with biological effector
domain to achieve cancer cell-specific death with preser-
vation of normal tissues.
Several strategies have been developed to target delivery of
therapy to tumors. (1) Physical targeting with either
directed radiation[11] or intratumoral injection[9]. (2)
Receptor-directed targeting with antibodies (for example,
Herceptin[12], rituximab[13]) or ligands (for example,
TRAIL[14]). (3) Prodrugs that are activated by enzymes
active in the local milieu (for example, MMP-9[15]). (4)
Differences in metabolic needs (for example,
Gleevec[16,17]). Each of these approaches has inherent
limitations, for example physical targeting has no ability
to treat distant metastases and the antibody- or ligand-
based targeting approaches are restricted to portions of
the tumor that are accessible to macromolecules.
In this study we have begun to explore whether small mol-
ecules that selectively accumulate in cancer cells may pro-
vide yet another approach to targeted therapeutic delivery.
A number of small molecules have been used in whole-
body imaging studies and preferentially accumulate in
tumors. One such class of small molecules is the family of
sigma-2 receptor ligands.
The sigma-2 receptor has been characterized as a molecule
that is highly expressed in rapidly proliferating cells and
down-regulated when cells become quiescent[18]. Sigma-
2 receptor expression has been reported in various human
cancer cells such as breast[19], brain[20], bladder[21],
colon and melanoma[22]; however, no studies have been
reported on sigma-2 receptor expression in pancreas ade-
nocarcinoma. Sigma-2 receptor-specific ligands have been
found to induce apoptosis [19-22], raising the possibility
that these ligands can act as sensitizers to standard chem-
otherapies.
Here we extend the body of evidence that the sigma-2
receptors are generic cancer markers by demonstrating
that the sigma-2 receptor are over-expressed in pancreatic
cancer cell lines in vitro and in Panc-02 tumor allografts
established in C57Bl/6 mice in vivo. We further demon-
strate that sigma-2 receptor ligands induce apoptosis in
pancreatic cancer cells via a caspase-3 dependent pathway.
And finally we show that systemic treatment with sigma 2
receptor-specific ligands slows the growth of established
tumors in allograft murine models of pancreatic cancer
without disrupting organ function.
Results
Sigma-2 receptor expression in vitro and in vivo
Murine pancreatic tumor cells (Panc-02) and human pan-
creas cancer cell lines (AsPC-1, CFPAC-1, Panc-1) bound
high levels of the sigma-2 receptor ligands in vitro (Figure
2A and 2B). Sigma-2 receptor ligands had minimal bind-
ing to single cell suspensions prepared from most normal
murine tissues including kidney, liver, lung, and brain.
Cells from spleen and pancreas exhibited higher binding
capacity for sigma-2 receptor ligands at the highest dose
tested (100 nM) and the spleen appeared to contain two
populations of cells with regard to sigma-2 receptor ligand
binding; however, even compared to the high KO5-138-
binding population of splenocytes, approximately 10-
fold more KO5-138 bound per cell to the syngeneic Panc-
02 tumors grown in vivo (Figure 2B). These findings trans-Page 2 of 12
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micro-PET (Figure 2C).
Binding assays
Direct saturation binding studies were carried out using
[3H]RHM-1 with membrane homogenates of PancO2
tumor allografts. Based on Scatchard analysis, the Kd and
Bmax values of the receptor-radioligand binding of
[3H]RHM-1 were 4.88 nM and 1250 fmol/mg protein
(Figure 3). The mean of nH values was close to unity, sug-
gesting that the receptor binding of [3H]RHM-1 displayed
one-site and non-cooperative binding characteristics.
Sigma-2 receptor ligand induces caspase-3/7 dependent 
cancer cell apoptosis
Treatment with sigma-2 specific ligands (WC26 and
SV119) and the sigma-1/sigma-2 promiscuous ligand
haloperidol caused dose-dependent apoptosis in all pan-
creas cancer cell lines tested. All cell lines tested had a
background rate of 10–15% apoptosis over the incuba-
tion period. At the highest dose tested (10 µM), all sigma-
2 receptor ligands induced an additional 10–20% of the
cells to undergo apoptosis (Figure 4A). The sigma-1 recep-
tor-specific ligand pentazocine had minimal toxicity to all
cell lines tested with the exception of CFPAC-1 which
exhibited an 8–10% increase in apoptosis at the highest
dose tested. The pan-caspase inhibitor (Z-VAD-fmk) and
caspase-3/7 inhibitor (DEVD-CHO) prevented sigma-2
receptor ligand-induced apoptosis in panc-02 cells, while
the caspase-1 inhibitor (YVAD-CHO) had no effect (Fig-
ure 4B). Similar results were seen with human pancreatic
cancer cell lines (AsPC-1, CFPAC-1, Panc-1, data not
shown).
In vivo treatment with a sigma-2 receptor ligand causes 
tumor apoptosis with minimal effects on normal tissues
Systemic administration of the sigma-2 receptor ligand
WC26 did not induce apoptosis in brain, lung, kidney or
spleen at any of the concentrations tested as measured by
FACS for active caspase-3 (Figure 5A). There was a small
amount of apoptosis (<10%) in the pancreas and livers of
these animals while their tumors had dose-dependent
increases in apoptosis (up to 50% of tumor cells were
active caspase-3 positive following a single 2 mg dose of
WC26, p < 0.0001). The mice appeared normal and no
apparent toxicity was noted in serum biochemistry data
(Figure 5B). There was a modest effect at the highest dose
of WC26 tested with elevated AST and depressed creati-
nine and glucose levels, though these values are still
within their reference ranges [23].
Sigma-2 receptor ligand therapy slows tumor growth and 
confers a survival advantage in vivo
The anti-tumor properties of sigma-2 receptor ligand
(WC26) monotherapy were evaluated in vivo in an estab-
lished syngeneic tumor model using Panc-02 cells in
C57BL/6 mice. Once tumors were established (5–8 mm
diameter), mice were randomized into one of three treat-
ment groups: daily intraperitoneal injection of 50 or 100
mg/kg of WC26 or vehicle control (20% DMSO, 200 µl)
once a day for five days. In both WC26 treatment groups,
tumors shrank during and immediately following treat-
ment while tumors in the vehicle-treated animals contin-
ued to grow (Figure 6A). Although regrowth occurred in
the Sigma-2 ligand treatment groups after treatment was
stopped, there was a significant delay compared to control
animals. Using tumor burden of 15 mm or ulceration as a
surrogate endpoint for survival, we found a significant
survival benefit in the Sigma-2 receptor ligand treatment
group (Figure 6B; p = 0.002). Based on blood chemistry
parameters, there was no acute, systemic toxicity observed
in any of the treated animals. In addition, no acute toxic-
ity was observed on immunohistochemical evaluation of
normal tissues after WC26 treatment (data not shown).
Discussion
We and others have shown that sigma 2 receptor-specific
ligands such as WC26 have both diagnostic and therapeu-
tic potential. Although the sigma 2 receptor has not been
identified, some characterization has occurred. It is an
approximately 20 kDa protein exclusively found in lipid
rafts throughout membrane encapsulated cellular com-
partments, yet it has resisted sequencing efforts. Pharma-
cologic studies suggest that the sigma 2 ligand binding site
is well conserved between rodents and primates, and we
have demonstrated that sigma 2 receptor-specific ligands
induce apoptosis in both mouse and human pancreas
adenocarcinoma cell lines equally.
Apoptosis is a crucial mechanism for cellular homeostasis
and failure of this mechanism is central to the develop-
ment of cancer and associated with resistance toward
adjuvant treatment such as chemo- or radiation thera-
pies[5,24]. Overexpression of anti-apoptotic proteins
including Bcl-2 family members and AKT/PKB pathway
agonists have been found in a variety of human cancers
including pancreas[25], breast[26], prostate [27] and
lung[28]. As a result, there is considerable interest in tar-
geting the intracellular apoptotic apparatus for cancer
therapy.
Sigma-2 receptor ligands have recently been reported to
induce apoptosis in several tumor cells in vitro [19-22].
Here we reported that sigma-2 receptor is highly expressed
in human and mouse pancreatic cancer cells, and sigma-2
receptor-selective ligands induce tumor apoptosis in a cas-
pase-3 dependent manner. Mouse and human pancreatic
cancer cell lines as well as established Panc-02 tumor allo-
grafts established in C57Bl/6 mice expressed the sigma-2
receptor at significantly higher levels than normal mousePage 3 of 12
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receptor ligand in the tumor could be used to image the
tumor in vivo. These findings suggest that sigma-2 receptor
ligands have potential utility for diagnostic imaging of
pancreatic cancer extending the spectrum of their utility
beyond what has previously been reported for breast can-
cer and supporting the hypothesis that the sigma-2 recep-
tor is a generic marker for cellular proliferation [18,29-
31].
Targeting the sigma-2 receptor may also have utility in
cancer treatment. Ligands to the sigma-2 receptor (WC26,
SV119, and haloperidol) caused dose-dependent apopto-
sis in all tumor cell lines in vitro, while the sigma-1 recep-
tor-selective ligand pentazocine did not cause cell death in
three of four pancreatic cancer cell lines. Interestingly the
CFPAC cell line underwent dose dependent cell death in
the pentazocine treatment group. Sigma-1 antagonists
have been shown to induce apoptosis[32], suggesting that
CFPAC cells may have a different defect in their apoptotic
program.
The mechanism of sigma-2 receptor ligand-induced cell
death has not been established. Previous studies have
reported that sigma 2 receptor-specific ligands induce
apoptosis in a p53- and caspase-independent manner by
causing oxidative stress and increasing the concentration
of intracellular ceramide [33,34]. Other groups have
shown that the caspase-dependent mitochondrial path-
way is activated in response to treatment with sigma 2
receptor-specific ligands [35]. Our results show that inhi-
bition of the executioner caspases abrogates WC26-
induced apoptosis in pancreas adenocarcinoma cell lines,
suggesting that sigma 2 receptor-specific ligand-induced
apoptosis may be cell type and/or ligand specific. Pan-
creas cancer cells incubated with sigma-2 receptor ligands
were found to have active caspase-3 within 4–6 hours and
DNA fragmentation within 20 hours (data not shown).
Furthermore, pan-caspase and caspase-3/7 specific inhibi-
tion rescued sigma-2 receptor ligand-treated cells from
death. Our data do not clarify whether sigma-2 receptor-
specific ligand-induced cell death occurs predominantly
by the mitochondrial (intrinsic) or receptor-mediated
pathway (extrinsic).
Structure of sigma ligands utilized in this paperFigure 1
Structure of sigma ligands utilized in this paper. Panel A: Haloperidol is a non-specific sigma-1 and sigma-2 receptor lig-
and. Panel B: Pentazocine is a sigma-1 specific ligand. Panel C: Sigma-2 receptor-specific ligands SV119 and WC26. Panel D: 
Chemically-labeled sigma-2 receptor-specific ligands K05-138 (fluorescein-labeled), RHM-1 (3H-labeled), and RHM-4 (18F-
labeled).Page 4 of 12
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Sigma-2 ligands preferentially bind to cancer as opposed to normal tissuesFigure 2
Sigma-2 ligands preferentially bind to cancer as opposed to normal tissues. (A): Single cell suspensions were pre-
pared from liver, lung, pancreas, brain, kidney, spleen and pancreatic tumors (panc-02 bearing mice). Single cell suspensions 
were incubated for 1 hour with KO5-138 (a fluorescent labeled sigma-2 receptor ligand, at 50 nM (thin doted line) or 100 nM 
(thick solid line) of ligand, or left unstained (thin solid line). FACS histograms demonstrate 100 fold more florescence in tumors 
compared to normal tissues. (B): Human pancreatic cancer lines (CFPAC-1, Panc-1, AsPC-1) demonstrate similar high degree 
of sigma-2 ligand binding to when compared to our murine model (Panc-02). Fluorescein signal peaks were shown in unstained 
control (thin solid line), 50 nM of ligand (dotted line), or 100 nM of ligand (thick solid line). The experiment was repeated twice 
with identical results. (C): Representative Micro PET/CT images of pancreas adenocarcinoma (Panc-02) bearing C57BL/6 mice 
administered RHM-4 (18F-labled sigma-2 ligand). The tumor indicated by arrows was approximately 1 cm3. The additional hot 
spot represents metastatic tumor in a regional lymph node.
Molecular Cancer 2007, 6:48 http://www.molecular-cancer.com/content/6/1/48Our results are consistent with previous reports describing
cancer cell-selectivity of sigma-2 receptor ligands as well
as the ability of these molecules to cause caspase-depend-
ent cell death (apoptosis) both in vitro and in vivo. By
establishing that pancreas cancer cell lines and Panc-02
tumor allografts established in C57Bl/6 mice respond
similarly to sigma-2 receptor ligands, we have extended
the utility of these molecules and are demonstrating the
generality of targeting the sigma-2 receptor for both diag-
nostic and therapeutic applications. Importantly, we
showed that 24 hours after a single dose of WC26 there
was significant tumor apoptosis in vivo with minimal
apoptosis in normal tissues. More apoptosis was observed
in Panc-02 cells grown in vivo than in the same cell line
grown in vitro. This result is likely due to the up to 20-fold
difference in concentrations of the sigma 2 receptor-spe-
cific ligand between these experiments, but could also be
due to differential sensitivity of the Panc-02 cells when
grown in 2-dimensional culture compared to the 3-
dimensional architecture adopted in vivo. Although a
small amount of caspase-3 activity was seen in normal
liver and pancreas in dissociated tissues, this finding was
not recapitulated in an immunohistochemical study of
normal tissues after WC26 treatment (data not shown).
Furthermore, there were no apparent, systemic side effects
in the WC26 treated animals (Figure 5B).
In addition to causing tumor cell apoptosis in vivo with
minimal peripheral toxicity, sigma-2 receptor ligand treat-
ment of tumor-bearing mice led to tumor stability and
regression in some animals. Although all tumors regrew
shortly after treatment was stopped, WC26-treated tumors
remained smaller and fewer ulcerated than tumors in
vehicle-injected control animals. Systemic therapy with
WC26 was successful in reducing tumor mass and/or
altering the course of tumor growth after therapy. If
patients with locally advanced pancreatic cancer respond
similarly to treatment with sigma-2 receptor ligands they
might become candidates for pancreatic cancer treatment.
Conclusion
Using small molecule probes we have demonstrated that
the sigma-2 receptor is selectively over-expressed on pan-
creas cancer cells both in vitro and in vivo. We have also
shown proof of principle that this finding can be
exploited for both diagnostic imaging and therapeutic
use. We have identified the sigma-2 receptor as a potential
target for the treatment of pancreas cancer; selectively trig-
gering or sensitizing tumor cells toward apoptosis.
Materials and methods
Sigma receptor compounds and chemicals
Sigma-1 and sigma-2 receptor ligands (Figure 1) were syn-
thesized as previously described [36]. Caspase inhibitors
(ZVAD-FMK, YVAD-CHO, and DEVD-CHO) were
obtained from Calbiochem (San Diego, CA). Unless oth-
erwise specified, all other materials were obtained from
Sigma-Aldrich (Saint Louis, Missouri, USA).
Cell lines
Mouse pancreatic cancer (Panc-02) and several human
pancreatic cell lines (CFPAC-1, AsPC-1, and Panc-1) were
maintained in supplemented RPMI containing glutamine
(2 mmol/L), pyruvate (1 mmol/L), penicillin and strepto-
mycin (100 IU/mL), and 10% FBS. All cell culture proc-
esses were carried out in a humidified atmosphere of 5%
CO2 at 37°C.
Sigma-2 expression study in vitro
Lung, liver, spleen, kidney, pancreas, brain and estab-
lished tumor from C57BL/6 mice were minced to 1-mm
in size and digested in a RPMI buffer containing 1 mg/ml
Scatchard analysis of [3H]RHM-1 binding to the sigma-2 receptors in membrane homogenates from Panc-02 tumor allograftsFigure 3
Scatchard analysis of [3H]RHM-1 binding to the 
sigma-2 receptors in membrane homogenates from 
Panc-02 tumor allografts. (A): Representative saturation 
binding experiments which show the total bound, non-spe-
cific bound and specific bound. (B): Representative Scatchard 
plots which were used to determine Kd and Bmax values.Page 6 of 12
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Sigma-2 receptor ligands induce apoptosis of pancreatic cancer cells via a caspase 3 dependent pathwayFigure 4
Sigma-2 receptor ligands induce apoptosis of pancreatic cancer cells via a caspase 3 dependent pathway. (A): 
Treatment with WC26, SV119 and haloperidol (Halo.) caused dose-dependent apoptosis in all pancreatic cancer cell lines 
tested. At the highest dose tested, all sigma-2 receptor ligands resulted in significant apoptosis (25–35%, p < 0.05). (B): Sigma-
2 related apoptosis was prevented by pan-caspase inhibitor (Z-VAD-fmk) and caspase-3/7 inhibitor (DEVD-CHO), while the 
caspase-1 inhibitor (YVAD-CHO) had no effect (Panc-02 cells).
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Systemic administration of Sigma-2 receptor ligand induces substantial tumor apoptosis without major toxicityFigure 5
Systemic administration of Sigma-2 receptor ligand induces substantial tumor apoptosis without major toxic-
ity. (A): Systemic administration of the sigma-2 receptor ligand WC26 induces considerable apoptosis in Panc-02 tumor allo-
grafts (up to 50% of tumor cells were active caspase-3 positive following a single 2 mg dose of WC26, p < 0.0001). Data 
reported as percent specific apoptosis (percent specific apoptosis = observed apoptosis – tissue specific background apopto-
sis). (B): The mice appeared normal and no apparent toxicity was noted in serum biochemical analysis or by immunohisto-
chemistry (data not shown). Reference ranges for the blood chemistry panel in C57Bl/6 mice: ALT: 18–184 U/L, AST: 55–251 
U/L, glucose: 174–335 mg/dL, amylase: 2595 +/- 212 U/L, BUN: 34–58 mg/dL, creatinine < 1.1 mg/dL.
Molecular Cancer 2007, 6:48 http://www.molecular-cancer.com/content/6/1/48collagenase (Sigma-Aldrich, St. Louis, MO) and 0.1 mg/
ml DNase (Sigma-Aldrich, St. Louis, MO) for 45 min to
obtain a single-cell suspensions. After filtering, contami-
nating erythrocytes were lysed in Ammonium Chloride
(ACK) buffer, pelleted and resuspended in PBS (pH 7.4).
Single cell suspensions were incubated for 1 hour with
KO5-138 (a fluorescent labeled sigma-2 receptor ligand,
Figure 1) at 50 nM or 100 nM of ligand, left unstained. All
lines were then washed 3 times with PBS, and evaluated
by Fluorescence Activated Cell Sorting (FACS).
Binding assays (Scatchard analysis)
The tritiated compound [3H]RHM-1 was synthesized by
American Radiolabeled Chemicals, Inc. (St. Louis, MO)
via O-alkylation of the corresponding phenol precursor as
previously described[37]; chemical purity was greater
than 99% and the specific activity of the radioligand was
80 Ci/mmol. Membrane homogenates were prepared
from ~400 mg Panc-02 mouse tumor allografts, which
were removed from tumor bearing mice and frozen on dry
ice immediately and stored at -80°C until used. Before
homogenization, the tumor allografts were allowed to
thaw slowly on ice. Tissue homogenization was carried
out at 4°C using a Potter-Elvehjem tissue grinder at a con-
centration of 1 g of tissue/ml of 50 mM Tris-HCl at pH
8.0. The crude membrane homogenate was then trans-
ferred to a 50 ml centrifuge tube and resuspended to a
concentration of 200 mg of tissue/ml of 50 mM Tris-HCl.
Additional homogenization was accomplished using an
Ultra-Turrax T8 polython homogenizer (IKA Works, Inc,
Wilmington, NC). The final homogenate was then centri-
fuged for 10 min at 1000 g, the pellet discarded and the
supernatant mixed by vortexing and stored at -80°C until
used. The protein concentration of the suspension was
determined (DC protein assay, Bio-Rad, Hercules, CA)
and averaged ~10 mg of protein/ml of stock solution.
Approximately 200 µg membrane homogenates were
diluted with 50 mM Tris-HCl buffer, pH 8.0 and incu-
bated with [3H]RHM-1 in a total volume of 150 µl at
25°C in 96 well polypropylene plates (Fisher Scientific,
Pittsburgh, PA). The concentrations of the radioligand
ranged from 0.1–18 nM. After incubation of 60 min, the
reactions were terminated by the addition of 150 µl of
cold wash buffer (10 mM Tris-HCl, 150 mM NaCl, pH
7.4, at 4°C) using a 96 channel transfer pipette (Fisher Sci-
entific, Pittsburgh, PA), and the samples harvested and fil-
tered rapidly to 96 well fiber glass filter plate (Millipore,
Billerica, MA) that had been presoaked with 100 µl of 50
mM Tris-HCl buffer, pH 8.0 for 1 hour. Each filter was
washed with 200 µl of ice-cold wash buffer for a total of
three washes. A Wallac 1450 MicroBeta liquid scintilla-
tion counter (Perkin Elmer, Boston, MA) was used to
quantitate the bound radioactivity[30], non-specific bind-
ing was determined from samples which contained 10 µM
RHM-1. The equilibrium dissociation constant (Kd) and
Systemic administration of sigma-2 receptor ligand slows tumor growth and improves survivalFigure 6
Systemic administration of sigma-2 receptor ligand 
slows tumor growth and improves survival. Mice with 
established pancreas tumors were treated with 5 days of 
WC26 in one of two dose ranges (2 mg/day, n = 9; Dash line 
or 1 mg/day n = 10; dashed line) or vehicle control (20% 
DMSO n = 10; solid line). (A): Mice treated with WC26 had 
smaller tumors compared to animals vehicle control (p < 
0.0001). The two treatment groups were not statistically dif-
ferent. The double-headed arrow denotes the treatment 
period (5 days). (B): Survival of mice treated with WC26 
compared favorably to the mice treated vehicle control (p= 
0.002). Survival endpoints were defined as tumor diameter 
>15 mm or tumor ulceration.Page 9 of 12
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mined by a linear regression analysis of the transformed
data using the method of Scatchard[38].
Data from saturation radioligand binding studies was
transformed to determine the Hill coefficient, nH, defined
as:
Bs is the amount of the radioligand bound specifically; L is
the concentration of radioligand. nH, Hill slope, was
determined from Hill plot of  versus logL.
Sigma-2 expression study in vivo
MicroPET (positron emission tomography)/CT Imaging
was performed to confirm the uptake of the sigma-2
receptor ligand after injection of [18F]4 labeled Sigma-2
ligand; RHM-4 in tumor bearing mice. Briefly, female
C57Bl/6 mice were implanted subcutaneously in the nape
of the neck with Panc-02 mouse pancreatic adenocarci-
noma cells (1.0 × 106 cells in 200 µl RPMI) 7–10 days
before the study date. Average tumor burden on the day of
imaging was ~1.0 cm3. The animals were injected with of
[18F]4 labeled Sigma-2 ligand via tail vein and imaged at
2 hours after injection.
Evaluation of cytotoxicity of sigma-2 ligands in vitro
Tumor cells were seeded at a density of approximately 0.2
× 106 cells per well in 12-well plates in 1.0 ml culture
medium. Cells were split and pre-incubated at 37°C in
humidified 5% CO2 for more than 24 hours (Panc-02)
and 48 hours (CFPAC-1, AsPC-1, Panc-1) to insure uni-
form growth conditions. Compounds were dissolved in
DMSO and added to the culture medium at the concentra-
tions indicated. The final concentration of DMSO in the
cell culture medium was less than 1%. The cells were then
incubated for 24 hours at 37°C in humidified 5% CO2.
The extent of apoptosis was subsequently measured as
previously reported[9]. Briefly, staining was performed on
trypsin-EDTA treated cultures that had been fixed with 1%
paraformaldehyde and 90% methanol. Cell pellets were
resuspended in TUNEL reagent (APO-BRDU kit, San
Diego, CA) or cleaved caspase-3 antibody (Cell Signaling
Technology, Inc. Boston, MA) and incubated overnight at
room temperature (TUNEL) or 4°C (cleaved caspase-3).
After washing, cells were resuspended in fluorescein anti-
body or 7-AAD buffer and incubated for 1 hour at room
temperature. Cell-associated fluorescence was determined
using a flow cytometry (FACScan, BD Biosciences) and
analyzed with CellQuest software (BD Biosciences).
Antitumor effect of sigma-2 receptor ligand in vivo
All studies were performed in accordance with an animal
protocol approved by the Washington University Institu-
tional Animal Care Facility. Female C57BL/6 mice (8–12
weeks old) were purchased from the NCI and acclimated
for at least 1 week before tumor implantation. All mice
were injected in the right flank with 200 µl of a single cell
suspension containing 1.0 × 106 Panc-02 cells. Treatment
of the tumors started 2 weeks after tumor implantation
when their size reached a mean diameter of 5–8 mm. To
evaluate the effect of sigma-2 receptor ligands both sys-
temically and on tumor in vivo, several mice were sacri-
ficed after a single treatment. Necropsy was performed
and single cell suspensions were prepared from retrieved
organs. The extent of apoptosis in these cells was meas-
ured by FACS (described above). For the survival study,
mice (N = 10 per group) were treated with sigma-2 recep-
tor ligand at the stated concentration or vehicle control
once a day for 5 days. Mean tumor diameter was meas-
ured three times each week. All mice were euthanized
when the tumors reached a mean diameter of 15 mm or
when the tumors ulcerated [39].
Statistical analysis
For in vivo experiments, Kaplan-Meier survival curves were
plotted and differences were compared using a log-rank
test. Tumor sizes and FACS results were analyzed using
linear mixed repeated measures models. Hypothesis tests
were corrected for multiple testing using a Hochberg step-
up procedure. A p-value of less than 0.05 was considered
significant for all analyses.
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